---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-032821"
form_type: "8-K"
ticker: "IKT"
cik: "0001750149"
company_name: "Inhibikase Therapeutics, Inc."
filed_at: "2025-02-24T23:59:59+00:00"
generated_at: "2026-05-26T06:03:34.262888+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Inhibikase acquires CorHepta for $15M in stock; appoints Cabell as President and Adams as CSO

## Summary
- Acquired CorHepta for $15M in stock: 4,979,101 shares issued (3,319,397 upfront, remainder contingent on milestone).
- Chris Cabell appointed President & Head of R&D; former CorHepta CEO and ex-CMO of Arena Pharmaceuticals.
- Vincent Aurentz appointed to Board; former EVP/Chief Business Officer at Arena (acquired by Pfizer for $6.7B).
- John Adams appointed Chief Scientific Officer; co-founder of CorHepta, former Head of Research at Arena.
- Dr. Cabell employment: $500K base, 45% bonus, 2.81M stock options vesting over 4 years.

## SEC filing metadata
- accession: 0001193125-25-032821
- form_type: 8-K
- ticker: IKT
- cik: 0001750149
- company_name: Inhibikase Therapeutics, Inc.
- filed_at: 2025-02-24T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1750149/000119312525032821/0001193125-25-032821-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1750149/000119312525032821/d889659d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-032821
- JSON: https://secwatch.observer/filing/0001193125-25-032821.json
- Plain text: https://secwatch.observer/filing/0001193125-25-032821.txt

## Key facts
- Executive change
  Vincent Aurentz was appointed as Class I director at Inhibikase Therapeutics, Inc..
  - Action: appointed
  - Role: Class I director
  source text: The Board also expanded its size from seven to eight directors and appointed Vincent Aurentz to serve as a Class I director of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1750149/000119312525032821/0001193125-25-032821-index.htm
- Executive change
  Chris Cabell was appointed as President and Head of Research and Development at Inhibikase Therapeutics, Inc..
  - Action: appointed
  - Role: President and Head of Research and Development
  source text: the Board appointed Chris Cabell as President and Head of Research and Development of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1750149/000119312525032821/0001193125-25-032821-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.